Does Cosentyx List Kidney Problems as a Side Effect?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, does not commonly cause kidney side effects in clinical trials or post-marketing data. The prescribing information reports no direct renal toxicity, with kidney-related adverse events occurring at rates similar to placebo (under 1%).[1][2]
What Do Clinical Trials and Real-World Data Show?
In phase 3 trials involving over 4,000 patients, serious kidney issues like acute kidney injury were rare (0.1-0.5%) and not linked causally to Cosentyx—often tied to underlying conditions or comorbidities. Long-term extensions up to 5 years confirmed no cumulative renal risk. Real-world registries, like the Psoriasis Longitudinal Assessment and Registry (PSOLAR), echo this, with no elevated kidney event signals versus other biologics.[1][3]
Could Pre-Existing Kidney Issues Affect Cosentyx Use?
Patients with moderate-to-severe kidney impairment (eGFR <60 mL/min) can use Cosentyx—no dose adjustment needed, as it's not primarily cleared by kidneys (mostly via proteolytic degradation). Novartis monitoring recommends baseline creatinine checks for at-risk groups, like those with diabetes or hypertension, but no black-box renal warnings exist.[1][2]
What Kidney Complaints Do Patients Report?
User forums and FDA adverse event reports (FAERS) occasionally mention symptoms like reduced urine output or flank pain, but these are anecdotal, low-frequency (<0.1% of 500,000+ reports), and often confounded by concurrent meds (e.g., NSAIDs) or disease flares. No causal link established; most resolve without stopping treatment.[4]
How Does Cosentyx Compare to Other Biologics on Kidney Safety?
Unlike some TNF inhibitors (e.g., infliximab, with rare glomerulonephritis cases), Cosentyx shows cleaner renal profile. Head-to-head data versus adalimumab or ustekinumab found no differences in kidney adverse events.[3][5]
[1]: Cosentyx Prescribing Information (Novartis, 2023)
[2]: Drugs.com - Cosentyx Side Effects
[3]: JAAD - Secukinumab Safety Review (2021)
[4]: FDA FAERS Database Query (2023)
[5]: Annals of Rheumatic Diseases - Biologic Safety Meta-Analysis (2022)